HIV drugs inhibit transfer of plasmids carrying extended-spectrum β-lactamase and carbapenemase genes

Research output: Contribution to journalArticlepeer-review

Standard

HIV drugs inhibit transfer of plasmids carrying extended-spectrum β-lactamase and carbapenemase genes. / Buckner, Michelle M C; Ciusa, M Laura; Meek, Richard W; Moorey, Alice R; McCallum, Gregory E; Prentice, Emma L; Reid, Jeremy P; Alderwick, Luke J; Di Maio, Alessandro; Piddock, Laura J V.

In: mBio, Vol. 11, No. 1, e03355-19, 25.02.2020.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{a59426ab18a14a9092a1d46a3d1e71a6,
title = "HIV drugs inhibit transfer of plasmids carrying extended-spectrum β-lactamase and carbapenemase genes",
abstract = "Antimicrobial-resistant (AMR) infections pose a serious risk to human and animal health. A major factor contributing to this global crisis is the sharing of resistance genes between different bacteria via plasmids. The WHO lists Enterobacteriaceae, such as Escherichia coli and Klebsiella pneumoniae, producing extended-spectrum β-lactamases (ESBL) and carbapenemases as {"}critical{"} priorities for new drug development. These resistance genes are most often shared via plasmid transfer. However, finding methods to prevent resistance gene sharing has been hampered by the lack of screening systems for medium-/high-throughput approaches. Here, we have used an ESBL-producing plasmid, pCT, and a carbapenemase-producing plasmid, pKpQIL, in two different Gram-negative bacteria, E. coli and K. pneumoniae Using these critical resistance-pathogen combinations, we developed an assay using fluorescent proteins, flow cytometry, and confocal microscopy to assess plasmid transmission inhibition within bacterial populations in a medium-throughput manner. Three compounds with some reports of antiplasmid properties were tested; chlorpromazine reduced transmission of both plasmids and linoleic acid reduced transmission of pCT. We screened the Prestwick library of over 1,200 FDA-approved drugs/compounds. From this, we found two nucleoside analogue drugs used to treat HIV, abacavir and azidothymidine (AZT), which reduced plasmid transmission (AZT, e.g., at 0.25 μg/ml reduced pCT transmission in E. coli by 83.3% and pKpQIL transmission in K. pneumoniae by 80.8% compared to untreated controls). Plasmid transmission was reduced by concentrations of the drugs which are below peak serum concentrations and are achievable in the gastrointestinal tract. These drugs could be used to decolonize humans, animals, or the environment from AMR plasmids.Importance: More and more bacterial infections are becoming resistant to antibiotics. This has made treatment of many infections very difficult. One of the reasons this is such a large problem is that bacteria are able to share their genetic material with other bacteria, and these shared genes often include resistance to a variety of antibiotics, including some of our drugs of last resort. We are addressing this problem by using a fluorescence-based system to search for drugs that will stop bacteria from sharing resistance genes. We uncovered a new role for two drugs used to treat HIV and show that they are able to prevent the sharing of two different types of resistance genes in two unique bacterial strains. This work lays the foundation for future work to reduce the prevalence of resistant infections.",
keywords = "CTX-M, E. coli, ESBL, K. pneumoniae, KPC, antimicrobial resistance, carbapenemase, carbapenemases, Carbapenemases, Carbapenemase, E. Coli, K. Pneumoniae, Antimicrobial resistance",
author = "Buckner, {Michelle M C} and Ciusa, {M Laura} and Meek, {Richard W} and Moorey, {Alice R} and McCallum, {Gregory E} and Prentice, {Emma L} and Reid, {Jeremy P} and Alderwick, {Luke J} and {Di Maio}, Alessandro and Piddock, {Laura J V}",
year = "2020",
month = feb,
day = "25",
doi = "10.1128/mBio.03355-19",
language = "English",
volume = "11",
journal = "mBio",
issn = "2150-7511",
publisher = "American Society for Microbiology",
number = "1",

}

RIS

TY - JOUR

T1 - HIV drugs inhibit transfer of plasmids carrying extended-spectrum β-lactamase and carbapenemase genes

AU - Buckner, Michelle M C

AU - Ciusa, M Laura

AU - Meek, Richard W

AU - Moorey, Alice R

AU - McCallum, Gregory E

AU - Prentice, Emma L

AU - Reid, Jeremy P

AU - Alderwick, Luke J

AU - Di Maio, Alessandro

AU - Piddock, Laura J V

PY - 2020/2/25

Y1 - 2020/2/25

N2 - Antimicrobial-resistant (AMR) infections pose a serious risk to human and animal health. A major factor contributing to this global crisis is the sharing of resistance genes between different bacteria via plasmids. The WHO lists Enterobacteriaceae, such as Escherichia coli and Klebsiella pneumoniae, producing extended-spectrum β-lactamases (ESBL) and carbapenemases as "critical" priorities for new drug development. These resistance genes are most often shared via plasmid transfer. However, finding methods to prevent resistance gene sharing has been hampered by the lack of screening systems for medium-/high-throughput approaches. Here, we have used an ESBL-producing plasmid, pCT, and a carbapenemase-producing plasmid, pKpQIL, in two different Gram-negative bacteria, E. coli and K. pneumoniae Using these critical resistance-pathogen combinations, we developed an assay using fluorescent proteins, flow cytometry, and confocal microscopy to assess plasmid transmission inhibition within bacterial populations in a medium-throughput manner. Three compounds with some reports of antiplasmid properties were tested; chlorpromazine reduced transmission of both plasmids and linoleic acid reduced transmission of pCT. We screened the Prestwick library of over 1,200 FDA-approved drugs/compounds. From this, we found two nucleoside analogue drugs used to treat HIV, abacavir and azidothymidine (AZT), which reduced plasmid transmission (AZT, e.g., at 0.25 μg/ml reduced pCT transmission in E. coli by 83.3% and pKpQIL transmission in K. pneumoniae by 80.8% compared to untreated controls). Plasmid transmission was reduced by concentrations of the drugs which are below peak serum concentrations and are achievable in the gastrointestinal tract. These drugs could be used to decolonize humans, animals, or the environment from AMR plasmids.Importance: More and more bacterial infections are becoming resistant to antibiotics. This has made treatment of many infections very difficult. One of the reasons this is such a large problem is that bacteria are able to share their genetic material with other bacteria, and these shared genes often include resistance to a variety of antibiotics, including some of our drugs of last resort. We are addressing this problem by using a fluorescence-based system to search for drugs that will stop bacteria from sharing resistance genes. We uncovered a new role for two drugs used to treat HIV and show that they are able to prevent the sharing of two different types of resistance genes in two unique bacterial strains. This work lays the foundation for future work to reduce the prevalence of resistant infections.

AB - Antimicrobial-resistant (AMR) infections pose a serious risk to human and animal health. A major factor contributing to this global crisis is the sharing of resistance genes between different bacteria via plasmids. The WHO lists Enterobacteriaceae, such as Escherichia coli and Klebsiella pneumoniae, producing extended-spectrum β-lactamases (ESBL) and carbapenemases as "critical" priorities for new drug development. These resistance genes are most often shared via plasmid transfer. However, finding methods to prevent resistance gene sharing has been hampered by the lack of screening systems for medium-/high-throughput approaches. Here, we have used an ESBL-producing plasmid, pCT, and a carbapenemase-producing plasmid, pKpQIL, in two different Gram-negative bacteria, E. coli and K. pneumoniae Using these critical resistance-pathogen combinations, we developed an assay using fluorescent proteins, flow cytometry, and confocal microscopy to assess plasmid transmission inhibition within bacterial populations in a medium-throughput manner. Three compounds with some reports of antiplasmid properties were tested; chlorpromazine reduced transmission of both plasmids and linoleic acid reduced transmission of pCT. We screened the Prestwick library of over 1,200 FDA-approved drugs/compounds. From this, we found two nucleoside analogue drugs used to treat HIV, abacavir and azidothymidine (AZT), which reduced plasmid transmission (AZT, e.g., at 0.25 μg/ml reduced pCT transmission in E. coli by 83.3% and pKpQIL transmission in K. pneumoniae by 80.8% compared to untreated controls). Plasmid transmission was reduced by concentrations of the drugs which are below peak serum concentrations and are achievable in the gastrointestinal tract. These drugs could be used to decolonize humans, animals, or the environment from AMR plasmids.Importance: More and more bacterial infections are becoming resistant to antibiotics. This has made treatment of many infections very difficult. One of the reasons this is such a large problem is that bacteria are able to share their genetic material with other bacteria, and these shared genes often include resistance to a variety of antibiotics, including some of our drugs of last resort. We are addressing this problem by using a fluorescence-based system to search for drugs that will stop bacteria from sharing resistance genes. We uncovered a new role for two drugs used to treat HIV and show that they are able to prevent the sharing of two different types of resistance genes in two unique bacterial strains. This work lays the foundation for future work to reduce the prevalence of resistant infections.

KW - CTX-M

KW - E. coli

KW - ESBL

KW - K. pneumoniae

KW - KPC

KW - antimicrobial resistance

KW - carbapenemase

KW - carbapenemases

KW - Carbapenemases

KW - Carbapenemase

KW - E. Coli

KW - K. Pneumoniae

KW - Antimicrobial resistance

UR - http://www.scopus.com/inward/record.url?scp=85079858783&partnerID=8YFLogxK

U2 - 10.1128/mBio.03355-19

DO - 10.1128/mBio.03355-19

M3 - Article

C2 - 32098822

VL - 11

JO - mBio

JF - mBio

SN - 2150-7511

IS - 1

M1 - e03355-19

ER -